Quest Diagnostics (DGX) showcases a solid performance, with marked insider trading activities from Director Vicky B. Gregg and SVP Mark E. Delaney selling shares. The company released its robust Q4 and full year 2024 financial results, and is optimistic about its 2025 outlook, leading to a 6.7% increase in the quarterly dividend to $0.80 per share. Among significant accolades, Quest Diagnostics features on Fortune's World's Most Admired Companies List for the 11th consecutive year. Several entities, including YANKCOM Partnership and Boston Trust Walden Corp, have initiated or increased their position in DGX, despite some divestment by others like Pacer Advisors Inc. JPMorgan Chase & Co and Truist Financial have each issued a new price target for DGX. Positive forecasts for DGX's stock price come from Mizuho and Barclays. There is a surge in short interest in the company. Quest Diagnostics marks its 11th year on Fortune's World’s Most Admired Companies list, and has also been named a 'Best Place to Work for Disability Inclusion' for the seventh year in a row. The company has completed the acquisition of LifeLabs and other lab assets, further expanding its services. Analysts foresee a strong performance for Quest Diagnostics in the future.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 08 Feb 2025 23:18:01 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 4
